Protalix BioTherapeutics, Inc. Net Income
Protalix BioTherapeutics, Inc. (PLX) reported Net Income of $3.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-12
- Protalix BioTherapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was $3.78M, a 2203.05% increase year-over-year.
- Protalix BioTherapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was $18.32M.
- Protalix BioTherapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$5.50M, a 184.76% decline year-over-year.
- Protalix BioTherapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was $2.35M, a 27.22% decline year-over-year.
- Protalix BioTherapeutics, Inc. net income (loss) attributable to parent for fiscal 2022 was -$14.93M.
- Protalix BioTherapeutics, Inc. net income (loss) attributable to parent for fiscal 2021 was -$27.58M.
- Protalix BioTherapeutics, Inc. net income (loss) attributable to parent for fiscal 2020 was -$6.52M.
- Protalix BioTherapeutics, Inc. net income (loss) attributable to parent for fiscal 2019 was -$18.28M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.78M 10-Q · filed 2026-08-12 | $22.09M 10-Q · filed 2026-08-12 | $16.59M derived: sum of 3 quarters · filed 2026-08-12 | $18.95M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $18.32M 10-Q · filed 2026-05-13 | $12.81M derived: sum of 2 quarters · filed 2026-05-13 | $15.17M derived: sum of 3 quarters · filed 2026-05-13 | $15.33M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | -$5.50M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | -$3.15M derived: sum of 2 quarters · filed 2026-04-30 | -$2.98M derived: sum of 3 quarters · filed 2026-08-12 | -$6.60M DEF 14A · filed 2026-04-30 | ||||
| 2025-09-30 | $2.35M 10-Q · filed 2025-11-13 | $2.52M derived: sum of 2 quarters · filed 2026-08-12 | -$1.10M 10-Q · filed 2025-11-13 | $5.39M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $164.00K 10-Q · filed 2026-08-12 | -$3.46M 10-Q · filed 2026-08-12 | $3.04M derived: sum of 3 quarters · filed 2026-08-12 | $6.28M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | -$3.62M 10-Q · filed 2026-05-13 | $2.88M derived: sum of 2 quarters · filed 2026-05-13 | $6.11M derived: sum of 3 quarters · filed 2026-05-13 | $3.91M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $6.49M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | $9.73M derived: sum of 2 quarters · filed 2026-04-30 | $7.53M derived: sum of 3 quarters · filed 2026-04-30 | $2.93M DEF 14A · filed 2026-04-30 | ||||
| 2024-09-30 | $3.24M 10-Q · filed 2025-11-13 | $1.03M derived: sum of 2 quarters · filed 2025-11-13 | -$3.56M 10-Q · filed 2025-11-13 | -$9.61M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-06-30 | -$2.20M 10-Q · filed 2025-08-14 | -$6.80M 10-Q · filed 2025-08-14 | -$12.84M derived: sum of 3 quarters · filed 2026-04-30 | -$14.69M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-03-31 | -$4.59M 10-Q · filed 2025-05-09 | -$10.64M derived: sum of 2 quarters · filed 2026-04-30 | -$12.49M derived: sum of 3 quarters · filed 2026-04-30 | $6.85M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2023-12-31 | -$6.04M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | -$7.90M derived: sum of 2 quarters · filed 2026-04-30 | $11.44M derived: sum of 3 quarters · filed 2026-04-30 | $8.31M DEF 14A · filed 2026-04-30 | ||||
| 2023-09-30 | -$1.85M 10-Q · filed 2024-11-14 | $17.49M derived: sum of 2 quarters · filed 2024-11-14 | $14.36M 10-Q · filed 2024-11-14 | $10.62M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2023-06-30 | $19.34M 10-Q · filed 2024-08-14 | $16.21M 10-Q · filed 2024-08-14 | $12.47M derived: sum of 3 quarters · filed 2025-03-17 | $8.90M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2023-03-31 | -$3.13M 10-Q · filed 2024-05-10 | -$6.87M derived: sum of 2 quarters · filed 2025-03-17 | -$10.44M derived: sum of 3 quarters · filed 2025-03-17 | -$15.77M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2022-12-31 | -$3.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$7.31M derived: sum of 2 quarters · filed 2025-03-17 | -$12.64M derived: sum of 3 quarters · filed 2025-03-17 | -$14.93M 10-K · filed 2025-03-17 | ||||
| 2022-09-30 | -$3.57M 10-Q · filed 2023-11-06 | -$8.90M derived: sum of 2 quarters · filed 2023-11-06 | -$11.19M 10-Q · filed 2023-11-06 | -$17.85M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2022-06-30 | -$5.33M 10-Q · filed 2023-08-07 | -$7.62M 10-Q · filed 2023-08-07 | -$14.29M derived: sum of 3 quarters · filed 2024-03-14 | -$18.49M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2022-03-31 | -$2.29M 10-Q · filed 2023-05-04 | -$8.95M derived: sum of 2 quarters · filed 2024-03-14 | -$13.15M derived: sum of 3 quarters · filed 2024-03-14 | -$24.39M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2021-12-31 | -$6.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$10.87M derived: sum of 2 quarters · filed 2024-03-14 | -$22.11M derived: sum of 3 quarters · filed 2024-03-14 | -$27.58M 10-K · filed 2024-03-14 | ||||
| 2021-09-30 | -$4.20M 10-Q · filed 2022-11-14 | -$15.44M derived: sum of 2 quarters · filed 2022-11-14 | -$20.91M 10-Q · filed 2022-11-14 | -$20.52M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-06-30 | -$11.24M 10-Q · filed 2022-08-15 | -$16.72M 10-Q · filed 2022-08-15 | -$16.32M derived: sum of 3 quarters · filed 2023-02-27 | -$20.76M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-03-31 | -$5.47M 10-Q · filed 2022-05-16 | -$5.08M derived: sum of 2 quarters · filed 2023-02-27 | -$9.52M derived: sum of 3 quarters · filed 2023-02-27 | -$13.66M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2020-12-31 | $397.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$4.04M derived: sum of 2 quarters · filed 2023-02-27 | -$8.19M derived: sum of 3 quarters · filed 2023-02-27 | -$6.52M 10-K · filed 2023-02-27 | ||||
| 2020-09-30 | -$4.44M 10-Q · filed 2021-11-15 | -$8.59M derived: sum of 2 quarters · filed 2021-11-15 | -$6.92M 10-Q · filed 2021-11-15 | -$6.63M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | -$4.15M 10-Q · filed 2021-08-16 | -$2.48M 10-Q · filed 2021-08-16 | -$2.19M derived: sum of 3 quarters · filed 2021-08-16 | -$5.75M derived: sum of 4 quarters · filed 2021-08-16 | ||||
| 2020-03-31 | $1.67M 10-Q · filed 2021-05-14 | $1.96M derived: sum of 2 quarters · filed 2021-05-14 | -$1.60M derived: sum of 3 quarters · filed 2021-05-14 | -$9.35M derived: sum of 4 quarters · filed 2021-05-14 | ||||
| 2019-12-31 | $291.00K 10-K · filed 2020-03-12 | -$3.27M derived: sum of 2 quarters · filed 2020-10-29 | -$11.01M derived: sum of 3 quarters · filed 2020-10-29 | -$18.28M 10-K · filed 2022-03-31 | ||||
| 2019-09-30 | -$3.56M 10-Q · filed 2020-10-29 | -$11.30M derived: sum of 2 quarters · filed 2020-10-29 | -$18.57M 10-Q · filed 2020-10-29 | -$24.00M derived: sum of 4 quarters · filed 2020-10-29 | ||||
| 2019-06-30 | -$7.74M 10-Q · filed 2020-08-10 | -$15.01M 10-Q · filed 2020-08-10 | -$20.44M derived: sum of 3 quarters · filed 2020-08-10 | -$25.76M derived: sum of 4 quarters · filed 2020-08-10 | ||||
| 2019-03-31 | -$7.26M 10-Q · filed 2020-06-01 | -$12.70M derived: sum of 2 quarters · filed 2020-06-01 | -$18.02M derived: sum of 3 quarters · filed 2020-06-01 | -$26.48M derived: sum of 4 quarters · filed 2020-06-01 | ||||
| 2018-12-31 | -$5.43M 10-K · filed 2020-03-12 | -$10.76M derived: sum of 2 quarters · filed 2020-03-12 | -$19.22M derived: sum of 3 quarters · filed 2020-03-12 | -$26.46M 10-K · filed 2021-03-30 | ||||
| 2018-09-30 | -$5.32M 10-K · filed 2020-03-12 | -$15.54M 10-Q · filed 2018-11-07 | -$13.78M derived: sum of 2 quarters · filed 2020-03-12 | -$21.02M 10-Q · filed 2019-11-07 | -$36.24M 10-Q · filed 2018-11-07 | -$34.33M derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-06-30 | -$8.46M 10-K · filed 2020-03-12 | -$11.29M 10-Q · filed 2018-08-09 | -$15.70M 10-Q · filed 2019-08-08 | -$20.69M 10-Q · filed 2018-08-09 | -$29.01M derived: sum of 3 quarters · filed 2020-03-12 | -$40.44M derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-03-31 | -$7.24M 10-K · filed 2020-03-12 | -$9.40M 10-Q · filed 2018-05-09 | -$20.54M derived: sum of 2 quarters · filed 2020-03-12 | -$31.98M derived: sum of 3 quarters · filed 2020-03-12 | -$31.53M derived: sum of 4 quarters · filed 2020-03-12 | |||
| 2017-12-31 | -$13.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$24.74M derived: sum of 2 quarters · filed 2020-03-12 | -$24.29M derived: sum of 3 quarters · filed 2020-03-12 | -$83.44M 10-K · filed 2020-03-12 | -$85.28M 10-K · filed 2018-03-06 | |||
| 2017-09-30 | -$11.44M 10-Q · filed 2019-03-18 | -$10.99M derived: sum of 2 quarters · filed 2019-03-18 | -$70.14M 10-Q · filed 2019-03-18 | -$72.76M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2017-06-30 | $450.00K 10-Q · filed 2019-03-18 | -$58.70M 10-Q · filed 2019-03-18 | -$61.32M derived: sum of 3 quarters · filed 2019-03-18 | -$68.61M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2017-03-31 | -$59.15M 10-Q · filed 2019-03-18 | -$61.77M derived: sum of 2 quarters · filed 2019-03-18 | -$69.06M derived: sum of 3 quarters · filed 2019-03-18 | -$79.92M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2016-12-31 | -$2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$9.91M derived: sum of 2 quarters · filed 2019-03-18 | -$20.77M derived: sum of 3 quarters · filed 2019-03-18 | -$29.36M 10-K · filed 2019-03-18 | ||||
| 2016-09-30 | -$7.29M 10-Q · filed 2017-11-08 | -$18.14M derived: sum of 2 quarters · filed 2017-11-08 | -$26.74M 10-Q · filed 2017-11-08 | $46.16M derived: sum of 4 quarters · filed 2018-03-06 | ||||
| 2016-06-30 | -$10.85M 10-Q · filed 2017-08-09 | -$19.45M 10-Q · filed 2017-08-09 | $53.45M derived: sum of 3 quarters · filed 2018-03-06 | $49.63M derived: sum of 4 quarters · filed 2018-03-06 | ||||
| 2016-03-31 | -$8.60M 10-Q · filed 2017-05-10 | $64.30M derived: sum of 2 quarters · filed 2018-03-06 | $60.48M derived: sum of 3 quarters · filed 2018-03-06 | $55.41M derived: sum of 4 quarters · filed 2018-03-06 | ||||
| 2015-12-31 | $72.90M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $69.08M derived: sum of 2 quarters · filed 2018-03-06 | $64.01M derived: sum of 3 quarters · filed 2018-03-06 | $58.04M 10-K · filed 2018-03-06 | ||||
| 2015-09-30 | -$3.82M 10-Q · filed 2016-11-09 | -$8.89M derived: sum of 2 quarters · filed 2016-11-09 | -$14.86M 10-Q · filed 2016-11-09 | -$23.33M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-06-30 | -$5.07M 10-Q · filed 2016-08-08 | -$11.04M 10-Q · filed 2016-08-08 | -$19.51M derived: sum of 3 quarters · filed 2017-03-16 | -$27.52M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-03-31 | -$5.97M 10-Q · filed 2016-05-09 | -$14.44M derived: sum of 2 quarters · filed 2017-03-16 | -$22.45M derived: sum of 3 quarters · filed 2017-03-16 | -$28.57M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2014-12-31 | -$8.47M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$16.48M derived: sum of 2 quarters · filed 2017-03-16 | -$22.60M derived: sum of 3 quarters · filed 2017-03-16 | -$29.94M 10-K · filed 2017-03-16 | ||||
| 2014-09-30 | -$8.01M 10-Q · filed 2015-11-09 | -$14.13M derived: sum of 2 quarters · filed 2015-11-09 | -$21.47M 10-Q · filed 2015-11-09 | -$32.36M derived: sum of 4 quarters · filed 2016-03-08 | ||||
| 2014-06-30 | -$6.12M 10-Q · filed 2015-08-10 | -$13.46M 10-Q · filed 2015-08-10 | -$24.35M derived: sum of 3 quarters · filed 2016-03-08 | -$30.10M derived: sum of 4 quarters · filed 2016-03-08 | ||||
| 2014-03-31 | -$7.34M 10-Q · filed 2015-05-07 | -$18.23M derived: sum of 2 quarters · filed 2016-03-08 | -$23.98M derived: sum of 3 quarters · filed 2016-03-08 | -$30.81M derived: sum of 4 quarters · filed 2016-03-08 | ||||
| 2013-12-31 | -$10.88M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | -$16.63M derived: sum of 2 quarters · filed 2016-03-08 | -$23.47M derived: sum of 3 quarters · filed 2016-03-08 | -$27.79M 10-K · filed 2016-03-08 | ||||
| 2013-09-30 | -$5.75M 10-Q · filed 2014-11-10 | -$12.58M derived: sum of 2 quarters · filed 2014-11-10 | -$16.91M 10-Q · filed 2014-11-10 | -$26.78M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-06-30 | -$6.84M 10-Q · filed 2014-08-07 | -$11.16M 10-Q · filed 2014-08-07 | -$21.04M derived: sum of 3 quarters · filed 2015-03-12 | -$26.51M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-03-31 | -$4.32M 10-Q · filed 2014-05-08 | -$14.20M derived: sum of 2 quarters · filed 2015-03-12 | -$19.68M derived: sum of 3 quarters · filed 2015-03-12 | -$10.04M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2012-12-31 | -$9.88M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | -$15.36M derived: sum of 2 quarters · filed 2015-03-12 | -$5.71M derived: sum of 3 quarters · filed 2015-03-12 | -$11.62M 10-K · filed 2015-03-12 | ||||
| 2012-09-30 | -$5.48M 10-Q · filed 2013-11-07 | $4.16M derived: sum of 2 quarters · filed 2013-11-07 | -$1.74M 10-Q · filed 2013-11-07 | -$10.65M derived: sum of 4 quarters · filed 2014-03-13 | ||||
| 2012-06-30 | $9.64M 10-Q · filed 2013-08-08 | $3.74M 10-Q · filed 2013-08-08 | -$5.17M derived: sum of 3 quarters · filed 2014-03-13 | -$14.05M derived: sum of 4 quarters · filed 2014-03-13 | ||||
| 2012-03-31 | -$5.90M 10-Q · filed 2013-05-09 | -$14.82M derived: sum of 2 quarters · filed 2014-03-13 | -$23.69M derived: sum of 3 quarters · filed 2014-03-13 | -$37.38M derived: sum of 4 quarters · filed 2014-03-13 | ||||
| 2011-12-31 | -$8.91M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-13 | -$17.79M derived: sum of 2 quarters · filed 2014-03-13 | -$31.48M derived: sum of 3 quarters · filed 2014-03-13 | -$36.53M 10-K · filed 2014-03-13 | ||||
| 2011-09-30 | -$8.88M 10-Q · filed 2012-11-07 | -$22.56M derived: sum of 2 quarters · filed 2012-11-07 | -$27.62M 10-Q · filed 2012-11-07 | -$36.14M derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2011-06-30 | -$13.69M 10-Q · filed 2012-08-03 | -$18.74M 10-Q · filed 2012-08-03 | -$27.27M derived: sum of 3 quarters · filed 2013-02-28 | -$29.74M derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2011-03-31 | -$5.05M 10-Q · filed 2012-05-09 | -$13.58M derived: sum of 2 quarters · filed 2013-02-28 | -$16.05M derived: sum of 3 quarters · filed 2013-02-28 | -$26.09M derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2010-12-31 | -$8.53M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | -$11.00M derived: sum of 2 quarters · filed 2013-02-28 | -$21.04M derived: sum of 3 quarters · filed 2013-02-28 | -$29.00M 10-K · filed 2013-02-28 | ||||
| 2010-09-30 | -$2.47M 10-Q · filed 2011-11-07 | -$12.52M derived: sum of 2 quarters · filed 2011-11-07 | -$20.47M 10-Q · filed 2011-11-07 | |||||
| 2010-06-30 | -$10.04M 10-Q · filed 2011-08-08 | -$18.00M 10-Q · filed 2011-08-08 | ||||||
| 2009-12-31 | -$31.44M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |